Peanut Allergy Treatment Market
Report ID: SQMIG35I2669
Report ID: SQMIG35I2669
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2669 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
91
|Figures:
76
Global Peanut Allergy Treatment Market size was valued at USD 536.80 Million in 2024 and is poised to grow from USD 598.16 Million in 2025 to USD 1421.78 Million by 2033, growing at a CAGR of 11.43% during the forecast period (2026-2033).
The unmet clinical need combined with increasing patient demand and prevalence of peanut allergies are the primary drivers of the peanut allergy treatment market trends. The treatment market is comprised of pharmaceuticals, biologics, diagnostics and clinical service models that allow for accurate diagnosis, graduated desensitization, and continued management, and is important to reduce the urgent health risk and long-term economic burden incurred by families and healthcare systems as a result of anaphylaxis. Prior to 1990, the care for peanut allergies focused primarily on avoiding exposures and carrying an emergency epinephrine auto-injector. In the last 10 years, research has continued to develop oral immunotherapy and immunomodulators for peanut allergy, which has led to the first oral desensitization product being approved by a government regulatory body, and significant investment by companies into this area around the world.
One of the most important aspects influencing peanut allergy treatment market growth is the reimbursement and clinical acceptance of therapies as a result of reproducible results from clinical trials; when payers begin to accept data on efficacy and safety for reimbursement, access to therapies expands, and companies can then grow their distribution network. An example of this is the introduction of a regulatory mechanism to support the structured use of oral immunotherapy with set procedures, trained specialists, and a pathway integrated into the clinic for administration and follow-up, resulting in the implementation of oral immunotherapy in real-world scenarios that have increased patient safety, decreased emergency department visits, and improved the quality of life for patients at all allergy centers. In turn, investors have provided funding for combination therapies that utilize biologics as adjuncts to immunotherapy; diagnostic companies have created component-resolved testing to help identify candidates for oral immunotherapy; and the proliferation of telemonitoring systems has facilitated the implementation of oral immunotherapy in more locations throughout the world.
How is AI Enabling Personalized Peanut Allergy Treatments?
Using AI to tailor peanut allergy treatment market share is accomplished through combining clinical records, immune profiles and multiomics for creating distinct patient types, thus creating a trajectory towards their treatment. Machine learning is used to integrate patient records, allergens, and the microbiomes of those individuals through the detection of their wearables to classify the likelihood of adverse events, calculate dosing schedules based on patient characteristics and to flag those patients with a higher proportion of likelihood of experiencing adverse events. Additional research into predicting the outcomes of oral food challenges and biomarker discovery is leading us away from the prior practice of “one-size-fits-all” immunotherapy and towards a more precision based approach to immunotherapy. This trend is encouraging both clinical programmes and investment into improving patient safety, experience and long-term compliance with immunotherapy
The March 2026 news release from DBV Technologies related to Viaskin patch late stage trials demonstrated a more effective opportunity of using their patch as a therapeutic option for patients with peanut allergy than the prior treatment option of avoidance of nuts. Artificial intelligence can expedite adoption of the Viaskin patch due to its ability to analyse patients in trials, predict who would gain the maximum benefit from this therapy and optimise monitoring patients post-approval for more efficiently evaluating patients and mitigating clinical risk.
Market snapshot - (2026-2033)
Global Market Size
USD 536.8 Million
Largest Segment
Oral Immunotherapy (OIT)
Fastest Growth
Targeted Biologics and Monoclonal Antibodies
Growth Rate
11.43% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global peanut allergy treatment market is segmented by treatment modality, patient demographic, end-user and region. Based on treatment modality, the market is segmented into oral immunotherapy (OIT), sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT), targeted biologics and monoclonal antibodies and others. Based on patient demographic, the market is segmented into pediatric (ages 4 to 17) and adult (ages 18 and above). Based on end-user, the market is segmented into hospitals and allergy centers, specialized immunology clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The oral immunotherapy segment is presently the largest segment due to its offering of the most clinically validated route to establish tolerance via controlled exposure and having a workflow that matches the current workflows of allergy clinics and familiarity of practitioners. The combination of established treatment protocols, a more straightforward regulatory pathway for oral products than other routes, and strong acceptance from physicians and patients are among the reasons for widespread adoption in practice settings. The ability of the treatment to be incorporated into the standard monitoring and reimbursement framework, along with the continued investments made by manufacturers, is an additional factor that creates a sustaining market demand for that product within its category, which has allowed it to remain in a leadership position in all healthcare settings.
On the other hand, epicutaneous Immunotherapy is currently one of the fastest-growing areas of Immunotherapy, primarily due to its favorable safety profile, ease of use/patch-based method of delivery, and high level of interest among families looking for lower-risk treatment options. The possibility of families administering this treatment at home, continued innovation in formulation of the patch, and renewed regulatory interest will continue to accelerate the market adoption of Epicutaneous Immunotherapy and provide new opportunities for expanding into new markets and creating more diverse treatment options.
Hospitals and allergy centers dominate the market for multi-disciplinary specialty expertise, allergy-specific units, and advanced monitoring/research capacity needed for multiple intensive desensitization protocols. Because they have credible institutional status and established referral channels, they can rapidly enroll patients into clinical trial or treatment programs. Because they have integrated billing and reimbursement, they are able to minimize barriers for access to their services. Their capability to manage adverse events and educate patients further reinforces doctors' confidence in providing high-volume services across all types of therapies.
In addition, special immunology clinics are the fastest-growing providers due to their narrow focus of expertise, flexible appointment times, and specific patient engagement strategies designed specifically for outpatient immunotherapy therapies. Their ability to quickly create new operational models, implement new protocols quickly, and provide high levels of physician/patient continuity allows them to drive higher adoption rates of newer therapies and build intimate communities for their specialized services.
To get detailed segments analysis, Request a Free Sample Report
North America leads the global peanut allergy treatment market due to an integrated ecosystem of research institutions, specialized clinical infrastructure, and concentrated investment in translational science. Strong collaboration among academic centers, pediatric allergists, and innovative biopharma firms accelerates therapy development and trial execution. Well-established regulatory pathways and payer engagement enable clearer commercialization pathways and earlier market adoption of novel immunotherapies and adjunctive treatments. High clinical awareness among healthcare professionals and comprehensive allergy networks support patient identification and competitive provision of care. Robust manufacturing capacity and venture funding further concentrate product development activity in the region, allowing rapid scale-up and regional centers of excellence that attract global talent and partnerships. Patient advocacy and coordinated registries improve real-world evidence generation and help shape clinical practice, while local market maturity fosters multiple therapeutic modalities reaching clinical use.
Peanut allergy treatment market outlook in the United States offering treatment for peanut allergies, this has allowed for rapid acceptance of therapies and innovative treatment solutions by utilizing established networks of allergology specialist clinics, research facilities and academia/industry collaborative relationships. Integrated care pathways and clinician advocates have assisted patients with their referrals and have increased their ability for proper management of patients with peanut allergies. Ongoing collaboration between public and private sectors in the form of research initiatives and participation by patient support organizations has fostered trial participation and awareness of trial availability to the public. With the presence of multiple pharmaceutical companies competing in this space and the significant number of established experts treating children with allergies, there will be a pathway for transitioning many innovative new therapies into practice by utilizing specialty care sites.
Peanut allergy treatment market forecast in Canada is demonstrating a cohesive nationwide strategy that leverages strong regional clinical networks and coordinated research collaborations aimed at improving access to clinical trials. The development of evidence-based studies and guidelines will be facilitated by vertically integrated specialist allergists, academic research institutions and other stakeholders involved in the care of patients with peanut allergies. Additional support for increasing the awareness of the peanut allergy through public engagement can be gained through patient advocacy groups, multidisciplinary clinics and professional associations, as well as international organizations working to improve the quality and quantity of available therapies. The public health care system has had an influence upon the treatment pathways and delivery of care provided through both private and public health care systems across Canada.
Rapid growth in Europe’s peanut allergy treatment market is supported by cooperation among researchers, rules and regulations that encourage research, and the increasing interest of governments in allergic diseases and their impact on public health. Multiple clinical development centres throughout Europe provide mechanisms for creating multi-centre clinical trials using consistent methodologies to gather evidence. Clinicians’ familiarity with immunotherapy options and integrated care pathways promotes a higher level of clinician engagement when diagnosing and treating peanut allergies. The combination of significant investment from specialized biopharmaceutical companies and partnerships with university researchers stimulates innovation. In addition, patient advocacy groups are creating demand for treatment and influencing treatment policy. Regulatory discussions between regulators / authorities and the biopharmaceutical industry encourage adaptability and flexibility of regulatory frameworks, and successful reimbursement negotiations in key healthcare markets provide a clearer approach to commercializing new treatments. The growing availability of local manufacturing and specialized clinical infrastructure make Europe an attractive location for developing and commercializing many different types of therapies.
Peanut allergy treatment market regional outlook in Germany provides a platform of abundant options for accomplishing a standard of high quality care. This is evidenced by a robust network supporting the pursuit of quality through the effectiveness of well-established academic leadership and funding of clinical research centers, while also providing a framework via national guidance committees and hospital-based Allergy Services for providing care along a standardized pathway, thus expediting the release of validated therapies for use in clinical practice. The combination of biotechnology innovators collaborating with University Clinic partners on various aspects of translational work creates opportunities for commercialization of more complex immunotherapy products/services/activities/services through specialty centers.
Peanut allergy treatment market regional forecast in the United Kingdom features an active environment for clinical trials, regulatory activity, and specialty care supporting faster development and commercialization for new therapies. There are strong collaborations between national research organizations, specialty clinics and biotech companies to help establish partnerships to recruit patients for clinical trials as well as create real-world evidence (evidence gathered outside of a clinical trial) about the effectiveness of new therapies. In addition, having open lines of communication with payers and clinical providers, and having informed patient advocates, promotes the successful integration of these new immunotherapies into traditional allergy care programs across the UK.
Peanut allergy treatment market penetration in France as, a result of increased focus on structured allergy care, increasing clinical research, and expanding networks of specialists to facilitate new therapeutic options. In addition, funding and investment in pediatric allergy centers and multidisciplinary clinics is increasing the accuracy of diagnosis and management of patients. Increased engagement of national professional societies, patient organizations, and professional associations has resulted in improvement of clinical practice guidelines related to allergy and greater awareness of allergies among all people. Additionally, collaboration with European consortia and biotech partner companies is increasing the availability of advanced immunotherapies through national coordinated care pathways.
In the Asia Pacific region, the peanut allergy therapy area is building on increased investment in research into clinical trial capabilities and the further extension of specialist services, together with strategic alliances with global innovators within this area. The combination of new Allergy Centers and increased activity in the area of clinical trials translates to additional evidence and treatment experience to the local area. There are technology-based platforms that allow patients to engage with their allergy doctor via telehealth and/or mobile applications, which results in better assessment and continuity of care. Regional biotech and multinational drug manufacturers are engaging in joint ventures to locally develop and manufacture products based on the clinical need within the region. By continuing to engage with regulators, provide ongoing training to Allergists, and introduce advanced immunotherapy products based on data derived from the use of laboratories, the ability to be able to implement new immunotherapy therapies is greatly enhanced in the region. Utilising telemedicine to provide greater access to diagnosis and treatment, in conjunction with a proactive approach to payers (i.e., Physician payers) and culturally tailored education, will increase the likelihood of patient accepting and continuing with their appropriate treatment.
Peanut allergy treatment industry in Japan has an advanced clinical research infrastructure and there are specialist allergy centres as well as a strong collaboration between industry and academic institutions, enabling therapies developed by academic institutions to be adapted to local practice. The improvement of paediatrics training in allergy and innovation in diagnostics contributes to an increased ability to identify and treat patients with peanut allergies. The ability to develop local clinical programs has been achieved through partnerships with international developers and manufacturers of high-quality products, as well as by working with patient advocates and regulators to facilitate the implementation and delivery of clinical programs at regional centres.
Peanut allergy treatment industry analysis in South Korea will be supported by the development of better clinics, better clinical networks, and collaboration between biotech and universities supporting the development of new therapies. Growth in the number of paediatric clinics using new diagnostics has improved the identification of patients with peanut allergies and has improved pathways for those patients to be treated. Partnerships with international developers through doc clinical initiatives in their region provide patients access to new therapies and support the clinician and patient engagement process to promote acceptance of these new therapies into the practice of allergy medicine.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Prevalence Of Peanut Allergy
Advances In Immunotherapy Approaches
High Cost Of Therapy Development
Complex Regulatory Approval Pathways
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment surrounding peanut allergy treatment primarily consists of M&A, regulatory partnerships, and novel delivery platforms. Large organizations have aggressively pursued acquisition strategies as a means to gain access to previously approved therapies. For example, Nestlé Health Science's acquisition(s) of Aimmune was a strategy by which Nestlé acquired the licensed peanut allergen therapy for Palforzia from Aimmune. Companies developing clinical stage therapies have likewise pursued focused funding strategies for their projects and created alliances/partnerships with regulatory agencies to assist in the licensure process for their devices (for example, DBV Technologies' epicutaneous patch).
Top Player’s Company Profile
Recent Developments in the Peanut Allergy Treatment Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global peanut allergy treatment market is poised for sustained growth. The key driver is unmet clinical need coupled with rising prevalence and patient demand for active interventions, while a second driver is rapid advances in immunotherapy approaches including oral and epicutaneous modalities that improve safety and convenience. A major restraint remains the high cost and complexity of therapy development and regulatory approvals which can slow new entrants and reimbursement. North America is the dominating region due to concentrated research, clinical infrastructure and payer engagement, and oral immunotherapy is the dominating segment because of stronger clinical validation and integration with existing allergy clinic workflows.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 536.8 Million |
| Market size value in 2033 | USD 1421.78 Million |
| Growth Rate | 11.43% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Peanut Allergy Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Peanut Allergy Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Peanut Allergy Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Peanut Allergy Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Peanut Allergy Treatment Market size was valued at USD 536.8 Million in 2024 and is poised to grow from USD 598.16 Million in 2025 to USD 1421.78 Million by 2033, growing at a CAGR of 11.43% during the forecast period (2026-2033).
Competitive dynamics in the peanut allergy treatment market center on strategic M&A, regulatory driven partnerships, and platform innovation. Major incumbents have pursued acquisitions to secure approved therapies, for example Nestlé Health Science's purchase of Aimmune for Palforzia. Clinical stage firms have raised targeted financing and struck regulatory alignments to accelerate devices such as DBV Technologies' skin patch toward licensure. 'Nestle', 'Aravive', 'Dbv Technologies', 'Prota Therapeutics', 'Camallergy', 'Intrommune Therapeutics', 'Allergy Therapeutics', 'Sanofi', 'Regeneron Pharmaceuticals', 'Genentech', 'Novartis', 'ALK-Abello', 'Stallergenes Greer', 'Aimmune Therapeutics', 'HAL Allergy Group', 'Desensitization Technologies', 'Cour Pharmaceutical', 'AnaptysBio', 'Siolta Therapeutics', 'InnoUp Farma'
Higher numbers of individuals affected by peanut allergy increase demand for effective therapeutic options, motivating pharmaceutical and biotech companies to prioritize research and development and allocate greater resources toward product pipelines and clinical programs. Greater patient populations raise awareness among healthcare providers and caregivers, encouraging earlier diagnosis and long-term management strategies that favor therapeutic intervention. This perceived and actual demand supports investment in novel immunotherapies and adjunctive treatments, expanding the range of development activities and commercial interest across the industry.
Patient Centric Therapeutic Pathways: Manufacturers and providers are shifting toward patient centric therapeutic pathways that emphasize convenience, safety and quality of life. Trend drives development of home based administration options, enhanced patient education, digital adherence tools and caregiver support. Clinical development increasingly incorporates patient reported outcomes and flexible visit schedules, while stakeholders prioritize shared decision making and personalized treatment. Payors and health systems show interest in care models that reduce disruption for patients and enable disease management tailored to individual lifestyles and preferences.
Why does North America Dominate the Global Peanut Allergy Treatment Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
